PL3773501T3 - Preparat dopochwowy - Google Patents

Preparat dopochwowy

Info

Publication number
PL3773501T3
PL3773501T3 PL19713800.1T PL19713800T PL3773501T3 PL 3773501 T3 PL3773501 T3 PL 3773501T3 PL 19713800 T PL19713800 T PL 19713800T PL 3773501 T3 PL3773501 T3 PL 3773501T3
Authority
PL
Poland
Prior art keywords
intravaginal formulation
intravaginal
formulation
Prior art date
Application number
PL19713800.1T
Other languages
English (en)
Inventor
Matthaios VIDALIS
Original Assignee
The Materia Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Materia Company Limited filed Critical The Materia Company Limited
Publication of PL3773501T3 publication Critical patent/PL3773501T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19713800.1T 2018-03-29 2019-03-28 Preparat dopochwowy PL3773501T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18165128 2018-03-29
PCT/EP2019/057925 WO2019185834A1 (en) 2018-03-29 2019-03-28 Intravaginal formulation

Publications (1)

Publication Number Publication Date
PL3773501T3 true PL3773501T3 (pl) 2024-03-11

Family

ID=61868297

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19713800.1T PL3773501T3 (pl) 2018-03-29 2019-03-28 Preparat dopochwowy

Country Status (14)

Country Link
US (2) US11850304B2 (pl)
EP (1) EP3773501B1 (pl)
DK (1) DK3773501T3 (pl)
ES (1) ES2968763T3 (pl)
FI (1) FI3773501T3 (pl)
HR (1) HRP20231675T1 (pl)
HU (1) HUE064590T2 (pl)
LT (1) LT3773501T (pl)
PL (1) PL3773501T3 (pl)
PT (1) PT3773501T (pl)
RS (1) RS64983B1 (pl)
SI (1) SI3773501T1 (pl)
SM (1) SMT202400035T1 (pl)
WO (1) WO2019185834A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137873B (zh) * 2022-07-26 2023-02-03 广西博生生物科技有限公司 一种用于阴道微生态调节的妇科流体敷料制剂的制备

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001151A (en) * 1972-10-30 1977-01-04 Warner-Lambert Company Anhydrous products having improved wettability characteristics
US3936402A (en) * 1972-10-30 1976-02-03 Warner-Lambert Company Anhydrous products having improved wettability characteristics, case 5
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US20110250626A1 (en) * 2002-09-09 2011-10-13 Reactive Surfaces, Ltd. Visual Assays for Coatings Incorporating Bioactive Enzymes for Catalytic Functions
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
CN101181636B (zh) * 2006-11-14 2010-09-15 北京金迪克生物技术研究所 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途
BRPI0809330B8 (pt) * 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
WO2009088553A1 (en) * 2007-10-22 2009-07-16 Board Of Regents, The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US10201576B2 (en) * 2012-05-18 2019-02-12 Ultratech India Limited Herbal composition for vaginal treatment
KR101496628B1 (ko) * 2013-02-19 2015-02-26 허정도 새로운 고점탄성 개질제 및 중온 개질제의 조성물과 그 제조방법 그리고 중온 개질 신규 및 재생 아스팔트콘크리트 혼합물의 조성물과 그 제조방법
UA118192C2 (uk) * 2015-10-22 2018-12-10 Юрій Захарович Толчеєв Противірусна фармацевтична композиція
MX2018010701A (es) * 2016-03-09 2019-03-28 Chu Sainte Justine Metodos para reducir la morbilidad y/o la mortalidad perinatal.

Also Published As

Publication number Publication date
WO2019185834A1 (en) 2019-10-03
LT3773501T (lt) 2024-01-10
DK3773501T3 (da) 2024-01-02
HUE064590T2 (hu) 2024-03-28
SI3773501T1 (sl) 2024-02-29
FI3773501T3 (fi) 2023-12-19
RS64983B1 (sr) 2024-01-31
ES2968763T3 (es) 2024-05-13
SMT202400035T1 (it) 2024-03-13
PT3773501T (pt) 2024-01-04
US20240091152A1 (en) 2024-03-21
HRP20231675T1 (hr) 2024-05-10
US20210030674A1 (en) 2021-02-04
US11850304B2 (en) 2023-12-26
EP3773501B1 (en) 2023-10-04
EP3773501A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
IL282617A (en) Aerosol formulation
IL276918A (en) Ophthalmic formulation
IL282567A (en) Aerosol formulation
IL282523A (en) Aerosol formulation
IL276011A (en) Formulation containing group b adenovirus
IL282589A (en) Aerosol formulation
GB201816447D0 (en) Formulation
IL282461A (en) Aerosol formulation
IL282697A (en) Aerosol formulation
GB201817863D0 (en) Aerosolisable formulation
IL284688A (en) formulation
GB201913232D0 (en) Aerosolisable formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
PT3773501T (pt) Formulação intravaginal
GB2587402B (en) Formulation
GB201817866D0 (en) Aerosolisable formulation
GB201809575D0 (en) Formulation
GB201906242D0 (en) Aerosolisable formulation
GB201804621D0 (en) Formulation
GB201900658D0 (en) Formulation
GB201806490D0 (en) Novel formulation
GB201806498D0 (en) Novel formulation
GB201819028D0 (en) Butanol-based formulations